<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d353">
    <sentence id="DDI-DrugBank.d353.s0" text="Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.">
        <entity charOffset="0-6" id="DDI-DrugBank.d353.s0.e0" text="Ethanol" type="drug"/>
        <entity charOffset="41-50" id="DDI-DrugBank.d353.s0.e1" text="etretinate" type="drug"/>
        <entity charOffset="95-103" id="DDI-DrugBank.d353.s0.e2" text="acitretin" type="drug"/>
        <entity charOffset="109-115" id="DDI-DrugBank.d353.s0.e3" text="ethanol" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s0.e0" e2="DDI-DrugBank.d353.s0.e1" id="DDI-DrugBank.d353.s0.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s0.e0" e2="DDI-DrugBank.d353.s0.e2" id="DDI-DrugBank.d353.s0.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s0.e0" e2="DDI-DrugBank.d353.s0.e3" id="DDI-DrugBank.d353.s0.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s0.e1" e2="DDI-DrugBank.d353.s0.e2" id="DDI-DrugBank.d353.s0.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s0.e1" e2="DDI-DrugBank.d353.s0.e3" id="DDI-DrugBank.d353.s0.p4"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s0.e2" e2="DDI-DrugBank.d353.s0.e3" id="DDI-DrugBank.d353.s0.p5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s1" text="Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.">
        <entity charOffset="0-12" id="DDI-DrugBank.d353.s1.e0" text="Glibenclamide" type="drug"/>
        <entity charOffset="56-64" id="DDI-DrugBank.d353.s1.e1" text="acitretin" type="drug"/>
        <entity charOffset="125-137" id="DDI-DrugBank.d353.s1.e2" text="glibenclamide" type="drug"/>
        <entity charOffset="142-153" id="DDI-DrugBank.d353.s1.e3" text="sulfonylurea" type="group"/>
        <entity charOffset="166-179" id="DDI-DrugBank.d353.s1.e4" text="chlorpropamide" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e0" e2="DDI-DrugBank.d353.s1.e1" id="DDI-DrugBank.d353.s1.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e0" e2="DDI-DrugBank.d353.s1.e2" id="DDI-DrugBank.d353.s1.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e0" e2="DDI-DrugBank.d353.s1.e3" id="DDI-DrugBank.d353.s1.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e0" e2="DDI-DrugBank.d353.s1.e4" id="DDI-DrugBank.d353.s1.p3"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s1.e1" e2="DDI-DrugBank.d353.s1.e2" id="DDI-DrugBank.d353.s1.p4" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e1" e2="DDI-DrugBank.d353.s1.e3" id="DDI-DrugBank.d353.s1.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e1" e2="DDI-DrugBank.d353.s1.e4" id="DDI-DrugBank.d353.s1.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e2" e2="DDI-DrugBank.d353.s1.e3" id="DDI-DrugBank.d353.s1.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e2" e2="DDI-DrugBank.d353.s1.e4" id="DDI-DrugBank.d353.s1.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s1.e3" e2="DDI-DrugBank.d353.s1.e4" id="DDI-DrugBank.d353.s1.p9"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s2" text="Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.">
        <entity charOffset="69-81" id="DDI-DrugBank.d353.s2.e0" text="glibenclamide" type="drug"/>
        <entity charOffset="111-119" id="DDI-DrugBank.d353.s2.e1" text="acitretin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s2.e0" e2="DDI-DrugBank.d353.s2.e1" id="DDI-DrugBank.d353.s2.p0"/>
    <negationtags>Repeating the study with 6 healthy male volunteers in the &lt;scope&gt; &lt;cue&gt; absence of &lt;/cue&gt; glibenclamide did not detect an effect of acitretin on glucose tolerance. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d353.s3" text="Careful supervision of diabetic patients under treatment with Soriatane is recommended.">
        <entity charOffset="62-70" id="DDI-DrugBank.d353.s3.e0" text="Soriatane" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s4" text="Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.">
        <entity charOffset="0-22" id="DDI-DrugBank.d353.s4.e0" text="Hormonal Contraceptives" type="group"/>
        <entity charOffset="103-111" id="DDI-DrugBank.d353.s4.e1" text="acitretin" type="drug"/>
        <entity charOffset="117-144" id="DDI-DrugBank.d353.s4.e2" text="combined oral contraceptives" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s4.e0" e2="DDI-DrugBank.d353.s4.e1" id="DDI-DrugBank.d353.s4.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s4.e0" e2="DDI-DrugBank.d353.s4.e2" id="DDI-DrugBank.d353.s4.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s4.e1" e2="DDI-DrugBank.d353.s4.e2" id="DDI-DrugBank.d353.s4.p2"/>
    <negationtags>Hormonal Contraceptives: It has &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d353.s5" text="However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.">
        <entity charOffset="38-46" id="DDI-DrugBank.d353.s5.e0" text="acitretin" type="drug"/>
        <entity charOffset="103-111" id="DDI-DrugBank.d353.s5.e1" text="progestin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s5.e0" e2="DDI-DrugBank.d353.s5.e1" id="DDI-DrugBank.d353.s5.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s6" text="Microdosed minipill progestin preparations are not recommended for use with Soriatane.">
        <entity charOffset="20-28" id="DDI-DrugBank.d353.s6.e0" text="progestin" type="drug"/>
        <entity charOffset="76-84" id="DDI-DrugBank.d353.s6.e1" text="Soriatane" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s6.e0" e2="DDI-DrugBank.d353.s6.e1" id="DDI-DrugBank.d353.s6.p0" type="advise"/>
    <negationtags>Microdosed minipill progestin preparations are &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; recommended for use with Soriatane. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d353.s7" text="It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.">
        <entity charOffset="30-58" id="DDI-DrugBank.d353.s7.e0" text="progestational contraceptives" type="group"/>
        <entity charOffset="140-148" id="DDI-DrugBank.d353.s7.e1" text="acitretin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s7.e0" e2="DDI-DrugBank.d353.s7.e1" id="DDI-DrugBank.d353.s7.p0"/>
    <negationtags>It is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d353.s8" text="Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.">
        <entity charOffset="0-11" id="DDI-DrugBank.d353.s8.e0" text="Methotrexate" type="drug"/>
        <entity charOffset="94-105" id="DDI-DrugBank.d353.s8.e1" text="methotrexate" type="drug"/>
        <entity charOffset="111-120" id="DDI-DrugBank.d353.s8.e2" text="etretinate" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s8.e0" e2="DDI-DrugBank.d353.s8.e1" id="DDI-DrugBank.d353.s8.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s8.e0" e2="DDI-DrugBank.d353.s8.e2" id="DDI-DrugBank.d353.s8.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s8.e1" e2="DDI-DrugBank.d353.s8.e2" id="DDI-DrugBank.d353.s8.p2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s9" text="Consequently, the combination of methotrexate with acitretin is also contraindicated.">
        <entity charOffset="33-44" id="DDI-DrugBank.d353.s9.e0" text="methotrexate" type="drug"/>
        <entity charOffset="51-59" id="DDI-DrugBank.d353.s9.e1" text="acitretin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s9.e0" e2="DDI-DrugBank.d353.s9.e1" id="DDI-DrugBank.d353.s9.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s10" text="Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.">
        <entity charOffset="0-8" id="DDI-DrugBank.d353.s10.e0" text="Phenytoin" type="drug"/>
        <entity charOffset="14-22" id="DDI-DrugBank.d353.s10.e1" text="acitretin" type="drug"/>
        <entity charOffset="51-59" id="DDI-DrugBank.d353.s10.e2" text="phenytoin" type="drug"/>
        <entity charOffset="85-93" id="DDI-DrugBank.d353.s10.e3" text="phenytoin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s10.e0" e2="DDI-DrugBank.d353.s10.e1" id="DDI-DrugBank.d353.s10.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s10.e0" e2="DDI-DrugBank.d353.s10.e2" id="DDI-DrugBank.d353.s10.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s10.e0" e2="DDI-DrugBank.d353.s10.e3" id="DDI-DrugBank.d353.s10.p2"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s10.e1" e2="DDI-DrugBank.d353.s10.e2" id="DDI-DrugBank.d353.s10.p3" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s10.e1" e2="DDI-DrugBank.d353.s10.e3" id="DDI-DrugBank.d353.s10.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s10.e2" e2="DDI-DrugBank.d353.s10.e3" id="DDI-DrugBank.d353.s10.p5"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s11" text="Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.">
        <entity charOffset="0-12" id="DDI-DrugBank.d353.s11.e0" text="Tetracyclines" type="group"/>
        <entity charOffset="26-34" id="DDI-DrugBank.d353.s11.e1" text="acitretin" type="drug"/>
        <entity charOffset="40-52" id="DDI-DrugBank.d353.s11.e2" text="tetracyclines" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s11.e0" e2="DDI-DrugBank.d353.s11.e1" id="DDI-DrugBank.d353.s11.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s11.e0" e2="DDI-DrugBank.d353.s11.e2" id="DDI-DrugBank.d353.s11.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s11.e1" e2="DDI-DrugBank.d353.s11.e2" id="DDI-DrugBank.d353.s11.p2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s12" text="Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.">
        <entity charOffset="0-8" id="DDI-DrugBank.d353.s12.e0" text="Vitamin A" type="group"/>
        <entity charOffset="19-27" id="DDI-DrugBank.d353.s12.e1" text="retinoids" type="group"/>
        <entity charOffset="60-68" id="DDI-DrugBank.d353.s12.e2" text="vitamin A" type="group"/>
        <entity charOffset="88-96" id="DDI-DrugBank.d353.s12.e3" text="retinoids" type="group"/>
        <entity charOffset="103-111" id="DDI-DrugBank.d353.s12.e4" text="acitretin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e0" e2="DDI-DrugBank.d353.s12.e1" id="DDI-DrugBank.d353.s12.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e0" e2="DDI-DrugBank.d353.s12.e2" id="DDI-DrugBank.d353.s12.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e0" e2="DDI-DrugBank.d353.s12.e3" id="DDI-DrugBank.d353.s12.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e0" e2="DDI-DrugBank.d353.s12.e4" id="DDI-DrugBank.d353.s12.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e1" e2="DDI-DrugBank.d353.s12.e2" id="DDI-DrugBank.d353.s12.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e1" e2="DDI-DrugBank.d353.s12.e3" id="DDI-DrugBank.d353.s12.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e1" e2="DDI-DrugBank.d353.s12.e4" id="DDI-DrugBank.d353.s12.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s12.e2" e2="DDI-DrugBank.d353.s12.e3" id="DDI-DrugBank.d353.s12.p7"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s12.e2" e2="DDI-DrugBank.d353.s12.e4" id="DDI-DrugBank.d353.s12.p8" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d353.s12.e3" e2="DDI-DrugBank.d353.s12.e4" id="DDI-DrugBank.d353.s12.p9" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s13" text="Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.">
        <entity charOffset="66-74" id="DDI-DrugBank.d353.s13.e0" text="acitretin" type="drug"/>
        <entity charOffset="80-89" id="DDI-DrugBank.d353.s13.e1" text="cimetidine" type="drug"/>
        <entity charOffset="92-98" id="DDI-DrugBank.d353.s13.e2" text="digoxin" type="drug"/>
        <entity charOffset="104-112" id="DDI-DrugBank.d353.s13.e3" text="glyburide" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s13.e0" e2="DDI-DrugBank.d353.s13.e1" id="DDI-DrugBank.d353.s13.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s13.e0" e2="DDI-DrugBank.d353.s13.e2" id="DDI-DrugBank.d353.s13.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s13.e0" e2="DDI-DrugBank.d353.s13.e3" id="DDI-DrugBank.d353.s13.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s13.e1" e2="DDI-DrugBank.d353.s13.e2" id="DDI-DrugBank.d353.s13.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s13.e1" e2="DDI-DrugBank.d353.s13.e3" id="DDI-DrugBank.d353.s13.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s13.e2" e2="DDI-DrugBank.d353.s13.e3" id="DDI-DrugBank.d353.s13.p5"/>
    <negationtags>Other: There appears to be &lt;scope&gt; &lt;cue&gt; no &lt;/cue&gt; pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d353.s14" text="Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.">
        <entity charOffset="34-42" id="DDI-DrugBank.d353.s14.e0" text="acitretin" type="drug"/>
        <entity charOffset="70-104" id="DDI-DrugBank.d353.s14.e1" text="anticoagulants of the coumarin type" type="group"/>
        <entity charOffset="107-114" id="DDI-DrugBank.d353.s14.e2" text="warfarin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s14.e0" e2="DDI-DrugBank.d353.s14.e1" id="DDI-DrugBank.d353.s14.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s14.e0" e2="DDI-DrugBank.d353.s14.e2" id="DDI-DrugBank.d353.s14.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d353.s14.e1" e2="DDI-DrugBank.d353.s14.e2" id="DDI-DrugBank.d353.s14.p2"/>
    <negationtags>Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed &lt;scope&gt; &lt;cue&gt; no &lt;/cue&gt; interaction. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d353.s15" text="Laboratory Tests If significant abnormal laboratory results are obtained, either dosage reduction with careful monitoring or treatment discontinuation is recommended, depending on clinical judgement."/>
    <sentence id="DDI-DrugBank.d353.s16" text="Blood Sugar: Some patients receiving retinoids have experienced problems with blood sugar control.">
        <entity charOffset="37-45" id="DDI-DrugBank.d353.s16.e0" text="retinoids" type="group"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s17" text="In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.">
        <entity charOffset="62-69" id="DDI-DrugBank.d353.s17.e0" text="retinoid" type="group"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s18" text="In diabetics, blood-sugar levels should be monitored very carefully."/>
    <sentence id="DDI-DrugBank.d353.s19" text="Lipids: In clinical studies, the incidence of hypertriglyceridemia was 66%, hypercholesterolemia was 33% and that of decreased HDL was 40%."/>
    <sentence id="DDI-DrugBank.d353.s20" text="Pretreatment and follow-up measurements should be obtained under fasting conditions."/>
    <sentence id="DDI-DrugBank.d353.s21" text="It is recommended that these tests be performed weekly or every other week until the lipid response to Soriatane has stabilized.">
        <entity charOffset="103-111" id="DDI-DrugBank.d353.s21.e0" text="Soriatane" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s22" text="Liver Function Tests: Elevations of AST (SGOT), ALT (SGPT) or LDH were experienced by approximately 1 in 3 patients treated with Soriatane.">
        <entity charOffset="129-137" id="DDI-DrugBank.d353.s22.e0" text="Soriatane" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s23" text="It is recommended that these tests be performed prior to initiation of Soriatane therapy, at 1- to 2-week intervals until stable and thereafter at intervals as clinically indicated.">
        <entity charOffset="71-79" id="DDI-DrugBank.d353.s23.e0" text="Soriatane" type="brand"/>
    </sentence>
</document>